Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals Inc (NQ: TARS )

16.07 -0.88 (-5.19%)
Streaming Delayed Price Updated: 11:43 AM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 48,446
Open 16.89
Bid (Size) 16.03 (1)
Ask (Size) 16.11 (2)
Prev. Close 16.95
Today's Range 15.89 - 16.89
52wk Range 11.33 - 25.25
Shares Outstanding 20,574,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings for Tarsus Pharmaceuticals
Via Benzinga
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire

Performance

YTD
+11.44%
+11.44%
1 Month
-7.54%
-7.54%
3 Month
-6.30%
-6.30%
6 Month
+32.05%
+32.05%
1 Year
-0.99%
-0.99%

More News

Read More
Tarsus to Present at Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
What 6 Analyst Ratings Have To Say About Tarsus Pharmaceuticals
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Why Shares of Tarsus Pharmaceuticals Are Up Thursday
Via The Motley Fool
Why Infosys Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Climbs to New 52-Week High
Via Investor Brand Network
Johnson & Johnson, Zions Bancorporation, Heritage-Crystal Clean And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023
Via Benzinga
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Present at the Jefferies Global Healthcare Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Via Benzinga
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.